Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study

Bone Marrow Transplantation volume 42, pages 337–343 (2008)Cite this article

Abstract

Oral and/or intestinal mucositis is a severe complication of hematopoietic SCT. Keratinocyte growth factor (KGF) has proven activity in the prevention of oral mucositis. We examined the efficacy of KGF in the prevention of intestinal mucositis. From January 2006 until December 2007, 35 consecutive patients underwent autologous SCT (auto-SCT) in our institution. A total of 15 consecutive patients who underwent auto-SCT from March 2007 to December 2007 received KGF for the prevention of mucositis and were included in the study group A, whereas 20 consecutive patients treated from January 2006 to March 2007, were included in the historical control group B. Oral and intestinal mucositis were significantly less severe in group A (P=0.002 and P<0.001, respectively). These results were confirmed with the use of video-capsule endoscopy. Patients in group A had a significantly lower incidence of neutropenic fever (P=0.026). Severe intestinal mucositis was significantly associated with a higher incidence of documented infections too (P=0.019). KGF is effective in the prevention of intestinal mucositis in patients undergoing auto-SCT. Patients with severe intestinal mucositis run a higher risk to develop infections.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ . Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000; 8: 33–39.

    CAS  PubMed  Google Scholar 

  2. Stiff PJ, Emmanouilides C, Bensinger WI, Gentile T, Blazar B, Shea TC et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006; 24: 5186–5193.

    Article  CAS  PubMed  Google Scholar 

  3. Balzan S, de Almeida Quadros C, de Cleva R, Zilberstein B, Cecconello I . Bacterial translocation: overview of mechanisms and clinical impact. J Gastroenterol Hepatol 2007; 22: 464–471.

    Article  CAS  PubMed  Google Scholar 

  4. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19: 2201–2205.

    Article  CAS  PubMed  Google Scholar 

  5. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST . The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82: 2275–2281.

    Article  CAS  PubMed  Google Scholar 

  6. Lark RL, McNeil SA, VanderHyde K, Noorani Z, Uberti J, Chenoweth C . Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis 2001; 33: 338–343.

    Article  CAS  PubMed  Google Scholar 

  7. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB . The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003; 98: 1531–1539.

    Article  PubMed  Google Scholar 

  8. Hill GR, Ferrara JL . The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754–2759.

    CAS  PubMed  Google Scholar 

  9. Finch PW, Rubin JS . Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv Cancer Res 2004; 91: 69–136.

    Article  CAS  PubMed  Google Scholar 

  10. Blijlevens N, Sonis S . Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2007; 5: 817–826.

    Article  Google Scholar 

  11. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–751.

    Article  PubMed  Google Scholar 

  12. Miller AB, Hoogstraten B, Staquet M, Winkler A . Reporting results of cancer treatment. Cancer 1981; 47: 207–214.

    Article  CAS  PubMed  Google Scholar 

  13. Brennan MT, von Bultzingslowen I, Schubert MM, Keefe D . Alimentary mucositis: putting the guidelines into practice. Support Care Cancer 2006; 14: 573–579.

    Article  PubMed  Google Scholar 

  14. Triantafyllou K, Dervenoulas J, Tsirigotis P, Ladas SD . The nature of small intestinal mucositis. A video-capule endoscopy study. Accepted for publication in Support Care Cancer 2008; e-pub ahead of print.

  15. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590–2598.

    Article  CAS  PubMed  Google Scholar 

  16. Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003; 21: 1452–1458.

    Article  CAS  PubMed  Google Scholar 

  17. Sonis ST . Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers? Nat Clin Pract Oncol 2005; 2: 134–135.

    Article  CAS  PubMed  Google Scholar 

  18. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M et al. Perspectives on cancer therapy-induced mucosal injury. Cancer 2004; 100 (Suppl 9): 1995–2025.

    Article  PubMed  Google Scholar 

  19. Diaz MA, Vicent MG, Madero L . High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Bone Marrow Transplant 1999; 24: 1157–1159.

    Article  CAS  PubMed  Google Scholar 

  20. Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 2008; 87: 43–48.

    Article  CAS  PubMed  Google Scholar 

  21. Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED et al. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 2004; 34: 581–587.

    Article  CAS  PubMed  Google Scholar 

  22. Argiris A, Seropian S, Cooper DL . High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Ann Oncol 2000; 11: 665–672.

    Article  CAS  PubMed  Google Scholar 

  23. Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451–458.

    Article  CAS  PubMed  Google Scholar 

  24. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998; 58: 933–939.

    CAS  PubMed  Google Scholar 

  25. Gibson RJ, Keefe DM, Clarke JM, Regester GO, Thompson FM, Goland GJ et al. The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 2002; 50: 53–58.

    Article  CAS  PubMed  Google Scholar 

  26. Brauchle M, Madlener M, Wagner AD, Augermeyer K, Lauer U, Hofschneider PH et al. Keratinocyte growth factor is highly overexpressed in inflammatory bowel disease. Am J Pathol 1996; 149: 521–529.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Lutgens L, Lambin P . Biomarkers for radiation-induced small bowel epithelial damage: an emerging role for plasma citrulline. World J Gastroenterol 2007; 13: 3033–3042.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Shapira M, Adler SN, Jacob H, Resnick IB, Slavin S, Or R . New insights into the pathophysiology of gastrointestinal graft-versus-host disease using capsule endoscopy. Haematologica 2005; 90: 1003–1004.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Second Department of Internal Medicine—Propaedeutic, Haematology Unit, Attikon University General Hospital, Medical School, University of Athens, Athens, Greece

    P Tsirigotis, K Girkas, V Giannopoulou, E Ioannidou, S Chondropoulos, G Papaxoinis, V Pappa, E Papageorgiou, T Economopoulos & J Dervenoulas

  2. Second Department of Internal Medicine—Propaedeutic, Hepatogastroenterology Unit, Attikon University General Hospital, Medical School, University of Athens, Athens, Greece

    K Triantafyllou, T Kalli & S D Ladas

Authors
  1. P Tsirigotis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Triantafyllou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Girkas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V Giannopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Ioannidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Chondropoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Kalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Papaxoinis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. V Pappa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E Papageorgiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T Economopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S D Ladas
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J Dervenoulas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Tsirigotis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsirigotis, P., Triantafyllou, K., Girkas, K. et al. Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. Bone Marrow Transplant 42, 337–343 (2008). https://doi.org/10.1038/bmt.2008.168

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.168

Keywords

This article is cited by

Search

Advanced search

Quick links